Synthesis and pharmacology of proteasome inhibitors

Angew Chem Int Ed Engl. 2013 May 17;52(21):5450-88. doi: 10.1002/anie.201207900. Epub 2013 Mar 25.

Abstract

Shortly after the discovery of the proteasome it was proposed that inhibitors could stabilize proteins which ultimately would trigger apoptosis in tumor cells. The essential questions were whether small molecules would be able to inhibit the proteasome without generating prohibitive side effects and how one would derive these compounds. Fortunately, "Mother Nature" has generated a wide variety of natural products that provide distinct selectivities and specificities. The chemical synthesis of these natural products finally provided access to analogues and optimized drugs of which two different classes have been approved for the treatment of malignancies. Despite these achievements, additional lead structures derived from nature are under investigation and will be discussed with regard to their biological potential and chemical challenges.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / chemical synthesis*
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Biological Products / chemical synthesis*
  • Biological Products / chemistry
  • Biological Products / pharmacology
  • Biological Products / therapeutic use
  • Cell Line, Tumor
  • Humans
  • Models, Molecular
  • Molecular Structure
  • Proteasome Endopeptidase Complex / chemistry
  • Proteasome Endopeptidase Complex / metabolism
  • Proteasome Inhibitors / chemical synthesis*
  • Proteasome Inhibitors / chemistry
  • Proteasome Inhibitors / pharmacology
  • Proteasome Inhibitors / therapeutic use
  • Structure-Activity Relationship
  • Ubiquitination / drug effects

Substances

  • Antineoplastic Agents
  • Biological Products
  • Proteasome Inhibitors
  • Proteasome Endopeptidase Complex
  • ATP dependent 26S protease